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Summary Patients with breast cancer treated with MPA often report an improvement in appetite. Similar
appetite stimulation is seen in patients treated with some corticosteroids, but MPA has a potential advantage
over these drugs in that it does not exert a catabolic effect. MPA (100 mg tds orally) has therefore been
compared with placebo in 60 patients with advanced malignant disease. Twenty-one patients in the MPA
group and 20 in the placebo group were receiving chemotherapy. Patients were treated for 6 weeks and were
assessed at weeks 0, 3 and 6 for appetite, energy, mood and pain using visual analogue scales. Nutritional
status was assessed by the measurement of serum proteins and anthropometrics. Karnofsky score was recorded
as a measure of performance status.
There was a significant improvement in appetite in the MPA group between weeks 0 (pre-study) and 3
(P = 0.0002) and 0 and 6 (P = 0.015). There was no significant improvement in appetite in the placebo group.
Supporting this finding was the significant increase in serum thyroid binding pre-albumin and retinol binding
protein in the MPA group between weeks 0 and 3 and 0 and 6 (P = 0.023 and P = 0.039 respectively). These
two parameters showed no significant change in the placebo group. There was no change in anthropometric
measurements, weight, performance status, energy, mood or pain in either group.
These data indicate that there was a significant increase in appetite in anorexic patients with advanced
cancer treated with MPA which was reflected in increases in rapid turnover proteins reported to reflect
nutritional status. However, this apparent increase in appetite did not result in improved weight, performance
status, energy levels, mood or relief of pain. Further studies to investigate the effect of higher doses of MPA
are indicated.
Anorexia is a debilitating symptom commonly experience by
cancer patients (Theologides, 1977). It is a component of
protein-energy malnutrition which is associated with a poor
prognosis, reduced response to anti-neoplastic therapy and a
reduced quality of life (Holmes & Dickerson, 1987). In a
study of 126 cancer patients receiving chemotherapy or
radiotherapy Padilla et al. reported that appetite and the
ability to eat were the most important factors in the physical
aspects of the patients' quality of life. These factors were
more important in determining quality of life than the ability
to work, physical strength or sexual satisfaction (Padilla,
1986). The background to this often profound loss of appe-
tite and the weight loss that accompanies cancer is complex
and agreement on the underlying mechanism has not been
reached (Bernstein & Symundi, 1980). Psychological, emo-
tional or physiological factors due to the disease and treat-
ment may initiate or worsen anorexia, but as the disease
progresses it is usually the cancer itself that is the main cause
of the anorexia (Theologides, 1977). In advanced cancer,
persistent and profound loss of appetite can present a
management problem. Steroids have been shown to increase
appetite but prolonged administration often causes unwanted
side effects to the patient.
Medroxyprogesterone acetate (MPA) is a synthetic deriva-
tive ofprogesterone used in the treatment of advanced breast
cancer, endometrial and prostatic cancer (Formelli et al.,
1982). It was noted that in the treatment of advanced breast
cancer with large doses of MPA (1-1.5 g/day), women exper-
ienced an increase in body weight associated with an improv-
ed appetite (Pannuti et al., 1982). The increase in body
weight was found to be the result of the anabolic effect of the
drug. This gives MPA an advantage over prednisolone which
has been used in the past to stimulate appetite in that it does
not cause catabolic side-effects in the patient. Side-effects of
MPA are infrequent and dose related and include hyperten-
sion, fluid retention, diabetogenic effect and the development
of a moon shaped face. The muscle wasting and myopathy
which are major problems when using long term cortico-
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steroids have only rarely been reported in the many hundreds
of patients treated with large doses of MPA (Ganzina &
Della Cuna, 1982).
A major difficulty inherent in the study of appetite and
nutritional status is the lack of suitable methods for deter-
mining protein energy malnutrition. In addition, it is difficult
to detect improvements in nutritional status which are speci-
fically attributable to increased protein intake and are not
related to non nutritional factors. Non invasive means of
investigating nutritional status have commonly relied on sim-
ple assessments such as weight, which is then related to ideal
body weight and usual body weight, and anthropometric
measurements such as triceps skin fold thickness and mid
arm circumference, both carried out on the non dominant
arm (Goodinson, 1987a). More recently a number of studies
have investigated the use of biochemical testing in nutritional
assessment, with particular reference to plasma proteins
(Mullen & Torosian, 1981; Inglebleek et al., 1975; Carpentier
et al., 1982; Ota et al., 1985; Thean et al., 1988; Weisberg,
1983). Those proteins most commonly utilised are serum
albumin (ALB), transferrin (TSN), thyroxine binding preal-
bumin (TBPA) and retinol binding protein (RBP). Of these
TBPA and RBP have consistently proved the most sensitive
in reflecting a decreased protein intake and are the first to
show an increase after nutritional therapy. The sensitivity of
these two proteins over ALB and TSN is related to their
short biological half-lives (RBP 12 h, TBPA 2 days, TSN 10
days, ALB 20 days) and rapid rate of synthesis when protein
intake is improved. The measurement of nitrogen balance has
been used to determine protein balance in the body (Wollard,
1980). This investigation requires a detailed, accurate record
of dietary intake over a 24 h period, and the collection of
24 h urine sample. Nitrogen input can be estimated from the
dietary record and total urinary nitrogen output from urinary
urea and creatinine. Accurate estimates of nitrogen balance
are therefore dependent on patient compliance.
The use of visual analogue scales (VAS) to quantify subjec-
tive feelings such as appetite is well recognised and has been
validated (Aitken, 1969). As an instrument they allow a
measurement of changes in subjective feelings within individ-
ual patients over a set time. These scales have been validated
for reliability, between subject reliability, test- retest reli-
ability and validity by Silverstone (1982).
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A Karnofsky performance score which objectively mea-
sures physical performance and dependence on a 100% scale
can be used to assess a patient's general well-being at entry
into the study and at subsequent assessments (Karnofsky &
Burchenel, 1949). Although there has been some debate of
the reliability of the scale (Schag et al., 1984) it is the most
widely used by Clinical Oncologists and has been proven to
correlate significantly with prognosis in a wide range of
tumours (Slevin & Staquet, 1986).
This paper reports a double-blind placebo controlled trial
of MPA in 60 patients with advanced malignant disease and
loss of appetite. Assessments of nutritional status involving
anthropometric measurements, nitrogen balance and bio-
chemical investigations for ALB, TSN, TBPA and RBP were
included in the study along with the use of visual analogue
scales to assess appetite, mood, energy and pain.
Prior to commencing the study a pilot study was carried
out using MPA (Farmitalia) at a dose of 100 mg three times
per day. All patients receiving the drug achieved an improve-
ment in appetite with only one patient reported any side-
effects. In view of the strong placebo effect known to occur
with appetite stimulants the study reported here was per-
formed on a double blind placebo controlled basis.
Methods
Sixty patients with advanced malignant disease were entered
into the study and randomised to receive either MPA (100
mg tds) or placebo, for 6 weeks. Verbal consent was gained
from each patient prior to entry into the study. Patients who
had recurrent or advanced solid tumours who may or may
not have received palliative intravenous chemotherapy were
eligible for entry into the study. Patients were matched for
whether or not they were receiving intravenous chemo-
therapy. Other criteria for entry was a loss of appetite and a
Karnofsky Performance score of 60% or greater (at 60%
patients require occasional assistance, but are able to care for
most of their own needs). Patients receiving corticosteroids
were excluded from the study, as were those with radiologic-
ally confirmed cerebral metastases or with gastro-intestinal
disease causing any obstruction or resulting in nausea or
vomiting.
At entry into the study and after 3 and 6 weeks patients
were assessed for appetite, energy, mood and pain using
visual analogue self assessment scales (VAS). The VAS scale
used in this study to measure appetite was as follows, 'How
would you describe your appetite on average lately?' At one
end of the 100 mm line was written, 'very poor, I rarely enjoy
my food these days' and at the other, 'I have a very good
appetite these days'. The patient was then asked to mark the
VAS at the point which they considered to be appropriate to
their appetite sensation at that time. Anthropometric
measurements of weight, mid arm circumference and triceps
skin fold on the non-dominant arm were recorded at each
assessment and blood was taken for the measurement of
ALB, TBPA, TSN and RBP. Each of these proteins were
measured by immunoassay. Patients were asked to keep a
dietary record for the 24 h prior to each assessment and to
collect a 24 h urine for the estimation of urinary nitrogen.
Changes within treatment groups were investigated using
the Wilcoxon matched pairs signed ranks test. A Mann-
Whitney test was used to investigate the differences between
the two groups.
Results
There was no difference between the two groups in age (mean
60 years in MPA group, 62 years placebo), Karnofsky per-
formance status (70 for MPA, 71 for placebo) or concurrent
chemotherapy (20 for MPA, 21 for placebo).
Lung cancer has a profound effect on appetite and there-
fore a grossly uneven distribution of lung cancer would have
made it difficult to intepret the results. A breakdown of
primary sites of disease for patients in each arm of the study
is shown in Table I, showing a similar number oflung cancer
patients in each arm of the study.
Forty-three patients completed two assessments and were
eligible for evaluation at week 3. Twenty-four of these
patients were in the MPA group and 19 in the placebo
group. Twenty-eight patients completed three assessments
and were eligible for final evaluation. Fifteen of these
patients were in the MPA group (six oat cell, nine other
tumours) and 13 (three oat cell lung, 10 other tumours) in
the placebo group. Of the 32 patients who failed to complete
the study most were withdrawn because of changes in treat-
ment or condition.
There was a significant improvement in appetite in the
MPA treated group between weeks 0 and 3 and 0 and 6. This
was accompanied by a significant improvement in TBPA and
RBP between weeks 0 and 6. In contrast there was no change
in these parameters in the group who received placebo. Per-
centage change in appetite (as recorded by visual analogue
scale), TBPA and RBP from week 0 are shown in Figure
la-c.
The results for all parameters are shown in Table II for the
MPA treated group and in Table III for the placebo treated
group. Although numbers of patients with oat cell lung
cancer were small (15 in the MPA cell, ten in the placebo
arm) analysis of them as a separate group showed a similar
improvement in appetite in both arms of the study, although
neither group showed an improvement in TBPA or RBP
proteins or overall increase in weight.
Those patients with other tumours who were receiving
placebo showed no significant improvement in appetite irre-
spective of whether or not they were receiving chemotherapy.
Nitrogen balance was not included in the final study analysis
as the dietary records made out by the patients often con-
tained information that was insufficiently precise, or, more
importantly, did not record portion size, thereby making
reliable estimates of dietary nitrogen intake impossible.
There were no differences between the two groups in
nausea, vomiting, diarrhoea, stomatitis or breathlessness.
Discussion
These data show a significant improvement in appetite as
measured by visual analogue scale in those patients receiving
MPA, between weeks 0 and 3 (P = 0.0002) and 0 and 6
(P = 0.015), and that this improvement was accompanied by
a significant increase in serum TBPA (P = 0.023) and RBP
(P = 0.039) over the same 6 week period. In contrast there
was no change in appetite, TBPA or RBP in the placebo
treated group.
Table I Primary sites of disease for patients in each arm of the
study
Diagnosis MPA group Placebo group
Oat cell lung 15 10
Squamous cell lung 1 4
Mesothelioma 2 3
Adenocarcinoma 1 3
Ca colon 3 1
NHL 3 1
Ca ovary 2 1
Ca breast 1
I
Myeloma 1 1
Ca adrenal 1 0
Hepatoma 0 1
Melanoma 0 1
Soft tissue sarcoma 0 1
Ca ileum 0 1
Ca nasopharynx 0 1
Total 30 301104 S. DOWNER et al.
a
**
-0- MPA arm
- Placebo arm
Table II Results for patients randomised to receive MPA
Week 0 Week 3 Week 6
n=30 n=24 n=15
VAS appetite 20.6 49.Oa 50.9b
VAS mood 45.5 52.1 52.0
VAS energy 29.4 37.9 38.0
VAS pain 10.5 13.1 13.6
Serum TBPA 129.7 152.7 171.4b
Serum RBP 37.5 43.2 44.9b
Serum TSN 2.0 2.0 2.0
Serum TIBC 43.0 44.0 44.2
Serum ALB 29.7 30.5 30.4
Weight 63.3 62.7 60.7b
Karnofsky PS 70.0 69.5 74.5
Arm circumference 24.9 24.6 24.4
Triceps skinfold 6.9 7.4 7.5
ap<0.01, Wilcoxon signed ranks matched pairs, compared to week
0.bp<0.05,Wilcoxonsignedranksmatchedpairs,compared toweek0.
b
Table III Results for patients randomised to receive placebo
Week 0 Week 3 Week 6
n=30 n= 19 n= 13
VAS appetite 24.4 35.5 32.0
VAS mood 46.6 46.5 53.1
VAS energy 24.3 26.5 24.8
VAS pain 19.2 11.7 21.8
Serum TBPA 104.1 97.8 98.1
Serum RBP 33.0 32.9 34.9
Serum TSN 1.9 1.9 1.9
Serum TIBC 43.0 42.0 43.7
Serum ALB 28.6 27.9 27.6
Weight 57.0 54.5 53.7
Karnofsky PS 71.2 69.3 70.0
Arm circumference 24.2 23.0 24.0
Triceps skinfold 6.7 8.1 8.3
C
Time (weeks)
Figure 1 a, Percentage change in appetite visual analogue score.
(**P<0.01, *P<0.05, compared to week 0). b, Percentage
change in thyroid binding pre-albumin (*P<0.05, compared to
week 0). c, Percentage change in retinol binding protein
(*P<0.05, compared to week 0).
Measurement of appetite in this study was carried out by
patient self-assessment. Patients often overestimate their
appetite (Wesdorp et al., 1983) which can lead to unrecog-
nised anorexia. However in this study changes in appetite
were measured within patients and not between patients, and
patients thus acted as their own controls. It was however not
possible to determine whether the improvement in appetite in
the actively treated arm was associated with an increased
dietary intake as portion sizes were not assessed.
Serum proteins have been reported to be useful in the early
detection of protein energy malnutrition (Inglebleek et al.,
1975). Using any of the protein indicators measured, the
range for the patients in this study was lower, or towards the
bottom of the normal range, of a healthy population, indicat-
ing decreased production of these proteins. There are, of
course, numerous other reasons why concentrations of these
proteins would be lowered in this group of patients (Mullen
& Torosian, 1981), but a decrease in levels of all four is
strong evidence for a decrease in production by the liver. The
two proteins generally regarded as being most sensitive to
decreased protein intake, TBPA and RBP, appeared to be
the most sensitive in this study. Plasma levels of both of
these are known to be influenced by other factors such as
circulating thyroid hormones and iron deficiency in the case
of TBPA, and deficiencies in vitamin A or trace metals for
RBP (Mullen & Torosian, 1981; Goodinson, 1987b). Indeed
a decreased level of RBP can be returned to normal by the
administration of vitamin A if that is the underlying defic-
iency (Muto et al., 1972). None of the patients in this study
had documented thyroid disease or symptomatic vitamin
deficiency (circulating levels were not measured). Such
arguments suggest that the increase in TBPA and RBP in the
MPA arm of the study may have been due to increased
intake of iron and vitamin A, rather than protein. However,
this would still indicate an improved nutritional intake in
those subjects on active treatment with MPA. The presence
of underlying infections can also influence levels of these
proteins, probably due to the redirection of protein synthesis
in the liver towards acute phase reactants.
It is widely recognised that urinary nitrogen balance
accounts for a considerable proportion of the nitrogen ex-
creted and can be determined precisely from an analysis of
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24 h urine sample. A decision was taken in the planning of
this study to carry out a basic evaluation of nitrogen intake
through dietary recall and of urinary nitrogen by collection
of 24 h urine. This was done in order to reduce the demands
made on patients involved in the study and also because the
specialised equipment and training required to carry out a
comprehensive nitrogen balance evaluation were not readily
available. Indeed the data collected were inadequate and
unfortunately not useful for analysis. Such an investigation
would not be attempted in this group of patients in future
studies.
Both arms of the study contained a high proportion of
patients with oat cell lung cancer, most of whom were receiv-
ing chemotherapy. Results show that these patients reported
a similar improvement in appetite in both arms of the study,
suggesting that in this group ofpatients a response to chemo-
therapy alone results in appetite improvement. This masks
any effect that may be exerted by the MPA. The use of MPA
100 mg tds to improve appetite and weight in patients with
oat cell lung cancer may not be appropriate, or a larger
dose may be required. The remainder of the patients in the
MPA group showed a dramatic improvement in appetite,
TBPA and RBP. These parameters were unchanged in the
group of patients with other tumours who were receiving
placebo.
Although this study demonstrates an improvement in
appetite and short half-life protein markers in patients
treated with MPA there was no improvement in either
weight, energy levels, Karnofsky performance score, mood or
albumin levels. It was believed that an improvement in appe-
tite would contribute to an improved quality of life of
patients which would be reflected in the visual analogue scale
assessment of mood and energy levels, but this was not
found. It may be that the use of this type of assessment is
not sensitive enough in this situaiton to detect any changes
that may occur, and a more comprehensive assessment, such
as the Hospital Anxiety and Depression (Zigmond & Snaith,
1983) scale or Rotterdam symptom checklist (De Haes et al.,
1990) may be more appropriate. Both groups of patients lost
weight over the study period. It seems reasonable to suggest
that as there was no increase in the longer half-life proteins
(ALB and TSN) over the 6 week study period, a stabilisation
or improvement in weight would be unlikely to result quickly
from prolongation of treatment at this dose.
In summary this study is the first to demonstrate an
improvement in appetite and nutritional protein markers in
patients receiving MPA 100 mg tds compared to placebo.
The improvement in appetite did not result in an improve-
ment in weight, longer half-life proteins, performance status,
mood, energy levels or relief of pain for the patient. It is
possible that this may be achieved by using larger doses of
MPA than that used in this study, or by prolonging the
treatment period. Further studies to investigate the effect of
larger doses of anabolic steroids in specific groups of patients
are now needed.
Inherent in carrying out such a study in this group of
patients is that their clinical condition may deteriorate during
the study period requiring withdrawal and incomplete collec-
tion of data. It must be emphasised that the selection of
suitable patients as well as specific choice of instrument for
measuring changes are of crucial importance when carrying
out such research.
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